Molecular Diagnostics Transforming the Pharmaceutical Market

Authors: By Dr. Sreten Bogdanovic and Dr. Beata Langlands

Publication date: September, 2002

Number of pages: 300+ Pages, 20 Exhibits, 31 Company Profiles 

The total market for molecular diagnostics is expected to grow at a compound annual growth rate of 16%-to $5 billion worldwide by 2007.

Advances in genomics are making it possible to choose therapy appropriate to an individual's genetic make-up.  

The translation of genomic information into novel molecular diagnostic products is taking place at both the gene and protein levels. New sophisticated diagnostic products are expected to appear at an accelerated rate. According to Dr. Francis Collins, director of the National Human Genome Research Institute at the NIH, predictive tests for around 25 conditions are likely to become available by 2010. 

D&MD's Molecular Diagnostics Market Report provides a global assessment of this promising industry through an exploration of the current landscape of this market, identification of the technology platforms being utilized in this field, and an examination of the major types of molecular diagnostic tests available. In addition, opportunities for the use of molecular diagnostics are discussed within the top eight world markets, and key companies presently engaged in the field are profiled. 

Unique Benefits of This Report:

» Identify viable technology drivers through a comprehensive look at various platform technologies for molecular diagnostics, including immunoassays (in particular rapid point-of-care formats), probe-based nucleic acid assays, microarrays, and sequencing

» Obtain a complete understanding of the chief molecular diagnostic tests-predictive, screening, prognostic, monitoring, pharmacogenomic, and theranostic-from their basic principles to their applications

» Discover feasible market opportunities via an identification of high-growth applications in different therapeutic areas, with a focus on the biggest and expanding markets-communicable diseases, cardiology, and oncology

» Focus on global industry development through an in-depth analysis of the major world markets for molecular diagnostics, including forecasts for growth

» Keep your eye on the primary companies engaged in molecular diagnostics with extensive profiles of their technologies, financial and partnering activities, product pipelines, and more. 

In-depth Company Profiles:

Abbott Laboratories Inc

AmpliStar

Bayer AG

Biopixel Ltd

Biosite Diagnostics Inc

Cepheid

Chembio Diagnostic Systems Inc

Chiron Corporation

Diagnostic Products Corporation

DiagnoSwiss SA

Digene Corporation

Genaissance Pharmaceuticals Inc

Gen-Probe Inc

HandyLab

Innogenetics NV

Interleukin Genetics

Matritech Inc

Meridian Bioscience Inc

Myriad Genetics Inc

Nanogen

Nymox Pharmaceutical

Ostex International

Qiagen

Quest Diagnostics Inc

Quidel Corporation

Roche Holding Ltd

SomaLogic

Tibotec-Virco NV

Variagenics

Visible Genetics Inc

Vysis Inc 

Available in two formats: CD-ROM  or PRINTED

Price: $4995.00

Publisher: Drug and Market Development 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/DMD_2003.html#a149